- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- HYCAMTIN, oral capsules, Radiation
- Drug · Radiation
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Hot Springs, Arkansas + 40 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Topotecan, Radiation therapy
- Drug · Radiation
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
- Interventions
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more
- Conditions
- Neuroblastoma
- Interventions
- DFMO, Celecoxib, Cyclophosphamide, Topotecan
- Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Gynecologic Tumors
- Interventions
- Oral Topotecan, Pazopanib
- Drug
- Lead sponsor
- Vector Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
- Interventions
- Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 16
- States / cities
- Jonesboro, Arkansas • Gainesville, Florida • Naples, Florida + 12 more
- Conditions
- Solid Tumor
- Interventions
- Oratopo
- Drug
- Lead sponsor
- Athenex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Liposarcoma, Recurrent Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
- Conditions
- Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma
- Interventions
- Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration, Topotecan Hydrochloride, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 13 Months to 21 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more